Solriamfetol in excessive daytime sleepiness: a profile of its use
Any type of resource available online.
Compliance with Ethical Standards
Disclosure: The preparation of this review was not supported by any external funding.
Conflicts of interest: Emma Deeks and Young-A Heo are salaried employees of Adis International Ltd./Springer Nature, are responsible for the article content and declare no relevant conflicts of interest.
Additional information about this Adis Drug Review can be found here
Oral solriamfetol (Sunosi™), a selective
dopamine and norepinephrine reuptake inhibitor, is approved to improve
wakefulness in adults with excessive daytime sleepiness (EDS) associated with
narcolepsy or obstructive sleep apnoea (OSA) in the USA and EU. In phase 3
trials in patients with narcolepsy or OSA, relative to placebo, solriamfetol within
the recommended dosage for narcolepsy (75–150 mg/day) or OSA (37.5–150 mg/day) improved
wakefulness and reduced sleepiness, together with patient- and clinician-rated
global improvements. The clinical benefits of solriamfetol were maintained with
longer-term treatment. Solriamfetol is generally well tolerated, with most
adverse events being of mild to moderate severity.